Aspire Biopharma Holdings (ASBP) Net Income Quarterly: History & Chart

Aspire Biopharma Holdings, Inc.(ASBP)

Biotechnology · Estero, FL

$8.85-0.03 (-0.34%)

Delayed quote: Oct 6, 2026, 9:44 AM EDT

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

Estero, FL

2 employees

aspirebiolabs.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kraig T. Higginson

View full financials

Quarterly Net Income

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly net income is ($1.27M) with QoQ Growth of +60.65%. Quarterly net income is profit after expenses, taxes, interest, and other items for the latest fiscal quarter.

Net Income TTM|Net Income CAGR|Profit Margin|Financials

Quarterly Net Income

ASBP Quarterly Net Income

$-1.27M

Reported quarterly net income; no daily interpolation. Q2 FY2026 (2026-06-30): $-1.27M.

≈164x over 10Y

ASBP P/E Ratio

Full P/E Ratio page

P/E Ratio

ASBP P/E Ratio Chart

N/A

FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:50:32.192Z. Historical observations retain their original dates. Historical series through 2024-03-11.

ASBP Earnings Yield

Full Earnings Yield page

Earnings Yield

ASBP Earnings Yield Chart

N/A

Unrounded diluted TTM EPS / FMP quote price × 100 Quote observation: 2026-10-06T13:50:32.192Z. Historical observations retain their original dates. Historical series through 2024-03-11.

Quarterly Net Income History

Period	Quarterly Net Income	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	($1.27M)	+60.65%	+35.99%
Q1 FY2026Period end 2026-03-31	($3.22M)	+31.54%	+79.78%
Q4 FY2025Period end 2025-12-31	($4.71M)	(154.40%)	(514.82%)
Q3 FY2025Period end 2025-09-30	($1.85M)	+6.60%	(755.64%)
Q2 FY2025Period end 2025-06-30	($1.98M)	+87.57%	(229.12%)
Q1 FY2025Period end 2025-03-31	($15.94M)	(1981.90%)	(546.16%)
Q4 FY2024Period end 2024-12-31	($765,710)	(254.05%)	(407.39%)
Q3 FY2024Period end 2024-09-30	($216,269)	+64.07%	N/A
Q2 FY2024Period end 2024-06-30	($602,000)	+75.60%	N/A
Q1 FY2024Period end 2024-03-31	($2.47M)	(1534.78%)	N/A
Q4 FY2023Period end 2023-12-31	($150,913)	N/A	N/A
Q3 FY2023Period end 2023-09-30	($69,258)	N/A	N/A
Q2 FY2023Period end 2023-06-30	$1.81M	(36.92%)	+1401.18%
Q1 FY2023Period end 2023-03-31	$2.87M	+28.80%	N/A
Q4 FY2022Period end 2022-12-31	$2.23M	+107.03%	N/A
Q3 FY2022Period end 2022-09-30	$1.08M	+792.53%	N/A
Q2 FY2022Period end 2022-06-30	$120,693	N/A	N/A
Q1 FY2022Period end 2022-03-31	($87,826)	N/A	N/A
Q4 FY2021Period end 2021-12-31	($755)	N/A	N/A
Q3 FY2021Period end 2021-09-30	($15,310)	N/A	N/A
Q2 FY2021Period end 2021-06-30	($2,383)	N/A	N/A
Q1 FY2021Period end 2021-03-31	($7,727)	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.